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Poly(propylene imine) dendrimers have been shown to be promising 3-dimensional polymers for the use in the pharmaceutical and
biomedical applications. Our aims of this study were first, to synthesize a novel type of dendrimer with poly(propylene imine) core and
maltose-histidine shell (G4HisMal) assessing if maltose-histidine shell can improve the biocompatibility and the ability to cross the blood-
brain barrier, and second, to investigate the potential of G4HisMal to protect Alzheimer disease transgenic mice from memory impairment.
Our data demonstrate that G4HisMal has significantly improved biocompatibility and ability to cross the blood-brain barrier in vivo.
Therefore, we suggest that a maltose-histidine shell can be used to improve biocompatibility and ability to cross the blood-brain barrier of
dendrimers. Moreover, G4HisMal demonstrated properties for synapse and memory protection when administered to Alzheimer disease
transgenic mice. Therefore, G4HisMal can be considered as a promising drug candidate to prevent Alzheimer disease via synapse protection.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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erative process characterized by the presence of senile plaques
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(Aβ), and by the presence of neurofibrillary tangles, mostly
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In this study, we used 3-dimensionally branched macromol-
ecules called dendrimers. Dendrimers are built by a series of
iterative synthetic steps from a small core molecule, propylene
imine in our case. Dendrimers have important features such as
controlled structure, nanoscopic size and high tunable availabil-
ity of multiple functional groups at their surface.7 In medical
applications, dendrimers have high potential as drug nanocar-
riers, imaging agents or as drugs per se.8 However, the ability to
cross the blood−brain-barrier (BBB) has been shown only for
few types of dendrimers, such as polyamidoamine (PAMAM)
dendrimer–drug conjugates,9–11 and maltose poly(propylene
imine) dendrimers.12 Previously we have reported that maltose
shell significantly reduces poly(propylene imine) (PPI) dendri-
mers of 3rd generation toxicity (G3Mal) in vivo and allows
G3Mal to cross blood−brain-barrier. However, in spite of
confirmed anti-amyloidogenic properties, G3Mal has not been
able to improve memory deficits in APP/PS1 transgenic mice.12
For the present study, we synthesized a novel type of
dendrimers: poly(propylene imine) dendrimers with a histidine-
maltose shell (G4HisMal). Histidine was selected due to several
reasons: is selectively transported through the BBB13 it has
chelating properties for Cu2+ ions14 which is considered to be
important since metal ion dyshomeostasis plays a detrimental
role in oxidative stress related to AD progression15; it has some
neuroprotective capacity.16 For dendrimers modification, histi-
dine was combined with maltose, since G3Mal has been proved
as non-toxic antiamyloidogenic agents capable to cross BBB.12
Here, we hypothesized that due to maltose PPI dendrimers may
keep anti-amyloidogenic properties meanwhile the added
histidine may help PPI dendrimer to cross BBB and will add
neuroprotective properties.
Using in vitro and in vivo models of AD, we characterized the
anti-amyloidogenic and neuroprotective properties G4HisMal.
Here we report that G4HisMal had significantly improved
biocompatibility and the ability of cross BBB. We proved that
G4HisMal crossed BBB, and did not accumulate in the brain
tissue being well-tolerated since treated no visible signs of
weaknesses or apathy in mouse behavior were recorded during
all period of chronic treatment. Strikingly, G4HisMal treatment
prevented memory decline during AD-like pathology. Our data
demonstrated that the positive cognitive effects induced by
G4HisMal in aged AD transgenic mice were not associated with
insoluble Aβ load reduction but with synapse protection.Methods
Reagents
PPI dendrimer of the 5th generation with 64 terminal amino
groups and 4th generation with 32 terminal amino groups was
obtained from SyMO-Chem (Eindhoven, The Netherlands) and
specified as 4th generation PPI dendrimers (PPI G4) and 3rd PPI
dendrimer (PPI G3) following the uniform nomenclature
description of polyamine dendrimers,17 this nomenclature was
also applied for other previously published PPI dendrimers and
cited in the present text (ref. 12, 35 and 36).Maltose monohydrate, L-histidine, sodium borate, boran
pyridine complex, and fluorescein-5/6-isothiocyanate (FITC)
were purchased from Sigma-Aldrich (Germany).
Aβ(1−40), with the amino acid sequence: [DAEFRHDS-
GYEVHHQKLVFFAEDVGSNKGAIIG LMVGGVV], was
obtained from JPT Peptide Technologies GmbH (Germany).
Aβ(1−42), with the amino acid sequence: [DAEFRHDS-
GYEVHHQKLVFFAEDVGSNKGAIIG LMVGGVVIA],
was obtained from Tocris (USA). Amyloid peptides were
dissolved in 10 mmol HEPES buffer (Sigma-Aldrich Spain,
Sweden) with 0.02 % NH3 at pH 12; stock concentration was
250 μmol; aliquots were kept at −80°C until use.Synthesis of G4HisMal dendrimer
Synthesis of G4HisMal was performed in two steps: First,
Poly(propylene imine) dendrimers of the 4th generation were
modified with His (G4His), then G4His was modified with
maltose (G4HisMal).
The whole conversion process was carried out under argon
protection atmosphere. G4 dendrimer (0.135 g (1 equivalent);
1.88×10-5 mol) was freeze-dried overnight, while anhydrous
DMSO (5 mL) was additionally pretreated under stirring in high
vacuum condition for several hours to dissolve freeze-dried G4
dendrimer and triethylamine (0.142 mL). A second reaction
solution was prepared to unify N-Boc-L-histidine (125 mg; 26
equivalents; 4.9×10-4 mol) and BOP (283 mg; 34 equivalents
related to N-Boc-L-histidine; 6.4×10-4 mol) in 10 mL anhydrous
DMSO and, then, stirred for 1 hour at room temperature. The
ester-activated N-Boc-L-histidine solution was slowly added to
the dendrimer solution. Then, the corresponding reaction mixture
was stirred for 24 hours at room temperature. The reaction
solution was intensively dialyzed in bidistilled water for 3 days
using dialysis tube with 1000 MWCO (ZelluTrans, Roth
(Germany), Flat with 45 mm) by exchanging bidistilled water
at least 3 times per day (5l beaker glass). To obtain solid material
for G4His with 99% yield 2-step freeze-drying was done by
reconstitution of the dialyzed product in 5 mL bidistilled water
for the second freeze-drying process. G4His was characterized
by 1H and 13C NMR and mass spectrometry (Supplementary
Figures 1-3).
G4His (0.1 g (1 equivalent); 7.5 × 10-6 M), D(+)-maltose
monohydrate (5.513 g (nearly 32 equivalents for each amino
group of G4His), 15.3 mmol), and borane-pyridine complex (3.4
mL; 15.3 mmol; 8 mol solution) were taken up in a sodium
borate buffer (15 mL; 0.1 mol). The reaction solution was stirred
at 50°C for 7 days. Then, the crude product was purified by
dialysis towards bidistilled water for 3 days, exchanging water at
least three times per day. G4HisMal was obtained from freeze-
drying process. The yield was (0.95 g, 72 %). Conversion of the
G4HisMal with FITC was used for the detection and mapping of
G4HisMal in cells and brain tissue. Synthesis of FITC-labeled
dendrimers was done as described.18 Synthetic pathways for
G4HisMal is presented in Figure 1. Description of characteri-
zation of dendrimers is described in Supplementary Information.
Figure 1. Structure and synthesis of G4HisMal. (A) Simplified structure of G4HisMal. Layers 1-4 indicate dendrimer’s branching points and generation of the
dendrimer. Layer 4 shows N terminal groups with maltose as R1 and histidine as R2 substituents. (B) Distance distribution functions P(R) of G4HisMal in PBS
calculated SAXS pattern of G4HisMal in PBS at 37°C using GNOM.40 Insertion: De novo three-dimensional reconstruction of the scattering entity of G4HisMal
using DAMMIF after 10 independent reconstructions. A line indicates the maximum dimension (Dmax), UCSF Chimera41 was used for visualization. The
SAXS raw data model fitting is shown in Supplementary Figure 7. (C) Reaction pathway for synthesizing glycodendrimer G4HisMal.
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The experiments carried out on male APP/PS1 and wild-type
mice. Two experimental treatment settings were designed,
covering short-term intranasal administration (BBB cross), and
long-term intranasal administration (treatment).BBB cross
Short-term intranasal administration was conducted in non-
transgenic littermates aged 6 months treated with FITC
−G4HisMal, or the PBS (n = 3 per group) by applying two
equal drops with a micropipet to each nasal cavity (5 μL),
resulting in a total dose of 10 mg/kg/body weight. After 1 hour,
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cold PBS pH 7.4 under deep whole-body anesthesia (ketamine/
xylazine, 5:1; 0.10 mL/10g/body weight, intraperitoneally).
When blood was cleaned up from the brain blood vessels, the
brains were removed, one brain hemisphere was homogenized,
while the second one was snap frozen and stored at −80°C until
use.
G4HIsMal treatment
At the age of 3 months animals were randomly divided as
follows: 7 transgenic and 6 WT mice received 5 μg per day
G4HisMal; 5 transgenic and 6 WT mice received the same
volume of PBS (5 μL). Long-term intranasal administration
lasted 3 months until animals reached of age of 6 months.
Memory evaluation tests were performed at the end of long-
term intranasal treatment using two object recognition test in a V-
maze (Panlab, Barcelona, Spain) as described.19
Fluorescent measurements of FITC-G4HisMal in mouse brain
tissue extract
Frozen brain tissues were homogenized in 5 volumes (wt/vol)
of TBS extraction buffer [140 mmol NaCl, 3 mmol KCl, 25
mmol Tris, pH 7.4, 5 mmol EDTA, and protease inhibitor
cocktail (Roche, Madrid, Spain)]. Homogenates were spun at
100000 g for 1 hour, and the supernatants were saved as the brain
soluble fractions. Quantitative determination of Aβ(1−40) and
Aβ(1−42) in brain soluble fractions was carried out using Aβ(1−40)
and Aβ(1−42) human ELISA kits (Invitrogen, U.S.A.) according
to the instructions of the manufacturer.
Fluorescent measurements were performed immediately after
preparation of tissue extracts, the fluorescence of FITC labeled
dendrimers was recorded at 485 nm excitation and 500−700 nm
emission wavelength as described.18 The background was set as
an intrinsic fluorescence of brain homogenate treated with PBS.
The content of FITC-labeled dendrimers was quantified with
standard curves of FITC-labeled dendrimers and expressed per
gram of tissue.
Double-labeling immunofluorescence and imaging
Brain tissue sections were immnolabeled as described19 with
combinations of primary antibodies (Supplementary Table 1)
according to manufacturer protocols. For Thioflavin S (Th S)
staining, sections were incubated with 1 % ThS (Sigma) in 70 %
ethanol for 10 minutes. For imaging, we used confocal
microscopes Leica TCS SP8 or Leica TCS (Leica Microsystems)
equipped with Diode 405/405 nm and Argon (405, 488, 552, 638
nm) lasers with an HP PL APO 63x/NA1.2 water immersion
objectives.
Immunofluorescence quantification
Amyloid burden was calculated as the percentage of the area
of amyloid deposition in plaques with respect to the total cortical
area. 9 pictures were taken from 3 different sections (-0.1 mm,
-1.5 mm and -2.0 mm from bregma) of each animal brain. The
pictures were taken from cingular/retrosplenial/motor cortex,
somatosensory cortex and piriform/entorhinal cortex per each
section. The areas selected were the main regions of the cerebralcortex in which Aβ is deposited in APP/PS1 mice. (n = 5, 6 per
group).The Aβ burden was quantified using Adobe Photoshop
CS4 software (Adobe Systems, San Jose, CA, USA) Specific
immunolabeling densities (glial response, oxidative stress) were
calculated in reference to the Aβ plaque area (6F/3D-positive) in
5 representative pictures taken from the cortex of each animal.
Fibrillar amyloid burden was calculated as the percentage of the
fibrillar (OC-positive) amyloid deposition area with respect to
the total 6E10-positive area.
Cell culture
Human neuroblastoma cell line SH−SY5Y was purchased
from the European Collection of Cell Cultures (ECACC) and
were grown as described.12 Primary neuronal cultures were
generated from wild-type (wt) mouse embryos as described.20
Statistical analysis
Results of memory tests were analyzed with two-way
ANOVA followed by Tukey’s post hoc test. The data from the
rest experiments tests were analyzed with one-way ANOVA
followed by Tukey’s post hoc test. In all the experiments, the
significance level was set at P b 0.05.
Ethical issues
All in vivo experiments were approved by ethics committees
of the Barcelona University (Principal Investigator: E. Aso) and
Lund University (Principal Investigator: G. Gouras). In all
experiments, we followed the guidelines of the Directive 2010/
63/EU. Animals were housed in specific pathogen-free the
Animal House of University of Barcelona and Lund University.
The animals were maintained in 12 h light/dark cycles in a
temperature regulated animal facility with free access to water
and food.Results
Maltose-histidine shell significantly improved the ability of poly
(propylene imine) dendrimers to cross BBB
PPI dendrimers of 4th generation with primary surface amino
groups were sequentially partially modified with histidine and
maltose as described21,22 (Figure 1, A-C). G4HisMal dendrimer
structure was characterized by NMR spectroscopy; mass
spectrometry; dynamic light scattering; synchrotron-based
small angle x-ray scattering (SAXS) and MALDI-TOF mass
spectroscopy: We determined the degree of substitution of
histidine and maltose on the outer shell as 26 histidine and 61
maltose units, with resulting molecular mass of 34000 g/mol
(Supplementary Figures 1–7). We used SAXS to study the
overall shape and structure of G4HisMal in solution. SAXS data
provided information on the shape and maximal diameter (6 nm)
of G4HisMal. Interestingly that three-dimensional reconstruction
of the scattering entity of G4HisMal revealed shell-like structure
(Figure 1, B)
Since nanoparticles can pass rapidly from the nose into the
brain along olfactory nerves, and the brain and brain stem along
branches of the first and second trigeminal nerve structures,23
Figure 2. G4HisMal dendrimers cross the BBB and inhibit Aβ(1−40) induced cell toxicity. (A) FITC fluorescence of brain tissue homogenates after i.n.
administration of FITC−G4HisMal and FITC−G4Mal. Statistics: Student’s t-test, data are expressed as a mean ± SD; n = 3 per group. (B) Fluorescence
microscopy images show the presence of FITC−G4HisMal in the cortex after i.n. administration of FITC−G4HisMal. The bar is 10 μm. (C) Aggregation of 20
μmAβ(1−40) in the presence of G4HisMal. (D) Transmission electron microscopy (TEM): samples were collected at the end of ThT kinetics as shown in (C). Bar
=100 nm. (E) MTT assay of Aβ(1−40) toxicity in the absence (dashed bar) and the presence of G4HisMal (gray bars). White columns correspond to control SH
−SY5Y cells; these values are taken as 1 of cell viability. The experiment was repeated twice in triplicate. Statistics: one-way ANOVA followed by Tukey’s post
hoc test, data are expressed as a mean ± SD. (F) Colocalization of FITC-G4HisMal dendrimers with Aβ(1−40) in SH−SY5Y cells. SH−SY5Y cells were treated
with 10 μmol Aβ(1−40) and 1 μmol G4HisMal after 24 hours of incubation, then cells were fixed and labeled with specific antibodies against Aβ(1−40) (red) 1
μmol and FITC against FITC-labeled dendrimers (green). Merge shows co-localization of Aβ(1−40) and FITC-G4HisMal. Aβ(1−40) fibrils and monomers were
used as controls as shown in Figure S9. Scale bar is 20 μm.
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of administration. To compare the ability to cross the BBB of
G4HisMal with precursor G3Mal, dendrimers were conjugated
with fluorescein isothiocyanate (FITC) as described.18 FITC-
G4HisMal and FITC-G3Mal dendrimers were administered
intranasally to six-month-old wild-type mice at a dose of 10
mg/kg/(body weight). Animals treated with PBS were used as
controls. One hour after treatment, animals were perfused with
PBS, when blood was cleaned up from the brain blood vessels,
the brains were removed FITC fluorescence in brain homogenate
was measured. Our result demonstrate that FITC-G4HisMal has
significantly improved ability to cross BBB compared to the
precursor dendrimer, FITC-G3Mal. The efficiency of FITC-
G3Mal to cross BBB is relatively low, as BBB penetration rate ofG3Mal in brain tissue does not exceed 6 % of a single dose
administered nasally to the mouse.12 To evaluate BBB
penetration rate of FITC-G4HisMal, we measured FITC
fluorescence of brain homogenates prepared from animals
treated with FITC conjugated G4HisMal, G4Mal and G3Mal.
We documented that FITC fluorescence of G4HisMal was 40 %
higher compared to maltose dendrimers, indicating that BBB
penetration rate was 8.4 % from the total dose of 10 mg/kg/body
weight used for intranasal administration. (Figure 2, A,
Supplementary Figure 8). Importantly, we measured BBB
cross of FITC-conjugated dendrimers, due to observed thera-
peutic effect of G4HisMal we suggest that non-conjugated
G4HisMal may have higher BBB penetration rate. Of note, if
brain perfusion were not sufficient to clean brain vessels from the
203E. Aso et al / Nanomedicine: Nanotechnology, Biology, and Medicine 17 (2019) 198–209blood completely, then detected fluorescence might come from
FITC-G4HisMal, which partially bypassed BBB. However, we
believe that both type of dendrimers did cross BBB since
transport of large molecular weight biologics into the brain along
trigeminal and olfactory nerves as occurs within a minute.24
The presence of FITC-G4HisMal in brain tissue was
confirmed by immunofluorescent labeling with an antibody
specific to FITC (Figure 2, B). Thus, immunolabeling and direct
measuring of FITC fluorescence demonstrated the presence of
FITC-G4HisMal in the brain tissue after i.n. administration,
indicating that FITC-G4HisMal dendrimers had crossed the
BBB. Importantly, modification of G4Mal with histidine
significantly improved the BBB cross 20 efficiency (Supple-
mentary Figure 8). G4HisMal did not accumulate in the brain
tissue after daily repeated i.n. administrations during one week
and measured by FITC fluorescence in brain homogenate (data
not shown).
Next, we tested G4HisMal capacity to interact with
Alzheimer's amyloid peptides. As demonstrated by Thioflavin
T (ThT) binding assay and electron transmission micrographs,
G4HisMal dendrimers did not prevent fibril formation but
clumped Aβ(1−40) fibrils together (Figure 2, C, D). Interestingly,
the intensity of ThT was significantly decreased following the
aggregation of Aβ(1−40). This observation can be explained that
G4HisMal may compete with ThT for binding to Aβ(1−40) or
G4HisMal may change Aβ(1−40) fibrillar resulting in lower ThT
fluorescence quantum yield.25,26 Similar results were obtained
for aggregation kinetic of Aβ(1−42) (Supplementary Figure 9).
Importantly, using electron microscopy, we did not detect any
Aβ oligomers in the presence of G4HisMal. Our data
demonstrated that G4HisMal significantly inhibit Aβ(1−40) cell
toxicity for human neuroblastoma cells (Figure 2, E): The
presence of 1 μmol G4HisMal, eliminated the toxicity of 10
μmol Aβ(1−40). Immunofluorescent labeling with a specific
antibody against Aβ(1-40), showed co-localization of Aβ(1−40)
and FITC-G4HisMal (Figure 2, F, Supplementary Figure 10).
Interestingly, as detected by immunofluorescence, monomeric
Aβ(1−40) was taken up by endocytic uptake,
27 while in the
presence of G4HisMal, Aβ(1−40) was not taken up by the cells.
Therefore, our data confirmed that when added to SHSY-5Y,
G4HisMal did not affect cell viability itself and inhibited Aβ(1
−40) induced cell toxicity.
Long-term G4HisMal treatment protects memory performance
in APP-PS1 mice without reducing amyloid plaque load
To test anti-amyloid properties of G4HisMal in vivo, APP/
PS1 mice were treated intranasally (i.n.) 5 μg/day of G4HisMal
same volume of PBS was used as a control. G4HisMal treatment
was started at the early pre-symptomatic stage when APP/Ps1
mice were 3 months of age and no memory impairment, nor
amyloid plaques are normally detected.19 Administration of
G4HisMal was repeated three times per week and continued
during three months until the APP/PS1 mice reached the age of 6
months when significant amyloid plaque load, synaptic loss, and
memory dysfunction were manifested.19 Age-matched wild-type
mice were used as a control. Importantly, during the complete
period of G4HisMal treatment, neither APP/PS1 nor wild-typemice did not demonstrate visible signs of weakness and apathy,
indicating that the compound was well-tolerated. At the end of
the treatment, after one week of drug wash-out period, all
animals were exposed to the two-object recognition test.
Strikingly, mice from APP/PS1 G4HisMal group demonstrated
significant memory improvement when compared with the
control mice, from APP/PS1-PBS group (Figure 3, A).
Surprisingly, Aβ plaque quantification did not show a reduction
in plaque load in the neocortex of treated APP/PS1 mice (Figure
3, B). However, we noticed distinct Aβ plaque morphology in
the brain tissue of treated animals when compared to the Aβ
plaques seen in the cortex of APP/PS1-PBS mice. To evaluate
amyloid plaque morphology, total Aβ deposits were labeled with
antibody 6E10; fibrillar Aβ was labeled with antibody OC.28
Analysis of the plaque area as a ratio of the fibrillar Aβ (OC
positive) against the total Aβ (6E10 positive) demonstrated a
significant elevation of fibrillar content in amyloid plaques after
G4HisMal treatment (Figure 3, C). Thus, G4HisMal modulated
plaque morphology in vivo. Of note, we could not detect direct
colocalization of amyloid plaque and G4HisMal in vivo, similar
to our in vitro experiment, since for the treatment we used
untagged G4HisMal.
Since inflammation and oxidative are strongly linked to
AD,29,30 we compared inflammation and oxidative stress
markers in the brain tissue around the amyloid plaques between
APP/PS1-G4HisMal and APP/PS1-PBS mice. Using GFAP and
Iba1, as the markers of glial response, we did not observed
significant differences around the amyloid plaques between
G4HisMal treated and PBS groups (Figure 4, A). Using HNE
and neuroketal as oxidative stress markers which have been
shown to be increased in AD,31,32 we did not detect significant
differences in oxidative stress markers around amyloid plaques
(Figure 4, B) nor in brain homogenate (Supplementary Figure
11). Taken together, results, shown in the Figures 3 and 4,
indicated that more fibrillar amyloid plaques observed in
G4HisMal group induced similar glial response and oxidative
stress effects compared to less fibrillar plaques observed in the
control PBS group. Therefore, we concluded that G4HisMal
modulated morphology of amyloid plaques was not a direct
cause of memory improvement after treatment.
Next, we quantified the levels and the ratio of soluble Aβ42 to
Aβ40, using specific enzyme-linked immunosorbent assays
(ELISA). Surprisingly, the ratio and levels of soluble Aβ42 to
Aβ40 also were not changed after the G4HisMal treatment
(Figure 5, A) indicating that as measured by ELISA, soluble Aβ
were not related to the memory improvement of APP/PS1 mice.
One possible explanation could be that for the memory loss in
control APP/PS1-PBS animals were responsible soluble Aβ
oligomers which could not be discriminated by ELISA. We
hypothesized that G4HisMal could protect neurons form soluble
Aβ oligomers. To test this hypothesis, we treated primary
neurons derived from wild-type mouse embryos with 1μmol of
freshly prepared of soluble Aβ(1-42) oligomers in the presence of
G4HisMal. Using a release of lactate dehydrogenase (LDH)
assay, we evaluated cell viability of cultured primary neurons in
the presence of Aβ(1-42) and G4HisMal. As it was reviled by
LDH assay, soluble Aβ(1-42) oligomers were the most toxic
species for cultured neurons, whereas monomers and fibrils did
Figure 3. Long-term G4HisMal treatment protects memory performance in APP-PS1 mice and attenuates the morphology of amyloid plaques. (A) Memory performance in the V-maze shows significant
improvement after treatment with G4HisMal. Statistics: two-way ANOVAwith genotype and treatment as between factors followed by Tukey’s post hoc test, data are expressed as a mean ± SEM. (B) Representative
immunohistochemical images of 6F/3D-positive amyloid depositions. Scale bar is 100 μm. Statistics: one-way ANOVA followed by Tukey’s post hoc test; data are expressed as a mean ± SEM. (C) Representative





















Figure 4. G4HisMal treatment does not modulate glial response and oxidative stress around Aβ plaques. (A) Glial response around amyloid plaques was not
changed after G4HisMal treatment. Representative images of double immunofluorescence labeling of GFAP (green) and Aβ (red) (left panel) and Iba1 staining
(red) and Aβ (green) (right panel) did not reveal a reduction of microglia and astrocytes around Aβ plaques after treatment. Scale bar is 50 μm. (B) Oxidative
stress around amyloid plaques was not altered after G4HisMal treatment. Representative images of double immunofluorescence labeling of HNE (red) and Aβ
(green) (left panel) and SOD2 staining (red) and Aβ (green) (right panel) did not detect a reduction of oxidative stress around Aβ plaques after treatment. Scale
bar is 50 μm. Statistics: one-way ANOVA followed by Tukey’s post hoc test; data are expressed as mean ± SEM.
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significantly reduced the neurotoxicity of soluble Aβ oligomers
(Figure 5, B). Therefore, we conclude that G4HisMal was able to
interfere with soluble neurotoxic Aβ(1-42) fraction reducing the
neurotoxicity of soluble Aβ(1-42) oligomers.
Preventive G4HisMal treatment protects synapses
To understand a possible mechanism behind the memory
rescue documented after G4HisMal treatment, we evaluated the
level of pre- and postsynaptic markers using specific antibodies
against drebrin, Pds95, and synaptophysin. All those synaptic
markers play a role in the synaptic plasticity and are down-regulated in AD.33,34 Western blotting with specific antibodies
against synaptic markers demonstrated that synaptophysin,
Psd95, and drebrin were up-regulated in brain homogenate of
APP/PS1 mice treated with G4HisMal, compared to the controls,
mice treated with PBS (Figure 6). Importantly, wild-type animals
treated with G4HisMal did not show a difference in the level of
synaptic markers as compared to wild-type PBS group
(Supplementary Figure 11). Thus, G4HisMal treatment protected
synapses in AD transgenic mice and was safe for wild-type mice.
To study one of the possible mechanisms of synapse protection,
we assayed the soluble fraction of brain homogenate using dot
blot with specific oxidative stress markers. Taken together, our
data demonstrated that first, G4HisMal protected synapses in the
Figure 5. G4HisMal reduces the toxicity of Aβ oligomers for cultured primary neurons. (A) Soluble Aβ quantification: Enzyme-linked immunosorbent assay
(ELISA), demonstrated that soluble Aβ was not changed in the brain extract of APP/PS1 G4HisMal mice. Statistics: one-way ANOVA followed by Tukey’s
post hoc test; data are expressed as mean ± SEM; n = 5 - 7 per group. (B) Left panel: Recombinant 10 μmol Aβ(1−42) was incubated at in PBS at 37°C. ThT
fluorescence variation was used to monitor aggregation of Aβ(1−42) (black line), red line corresponds to ThT alone. The arrows indicate the time when aliquots of
Aβ(1−42) monomers (AβM), oligomers (Aβ O), and fibrils (Aβ F) suspensions were taken for neuronal viability assay. Right panel: Wild-type primary neurons
were treated for one hour with 1 μmol Aβ(1−42) monomers (AβM), oligomers (Aβ O), and fibrils (Aβ F), G4HisMal significantly reduces cytotoxicity of AβO.
Statistics: one-way ANOVA followed by Tukey’s post hoc test, data are expressed as a mean ± SD, n = 3 embryos per group.
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in presymptomatic phase of AD could be an avenue for AD
treatment and third, G4HisMal is a potential drug candidate for,
synapse protection in presymptomatic phase of AD.Discussion
Alzheimer’s disease is a fatal neurodegenerative disorder and
the most common cause of dementia in the elderly. Genetics
strongly supports the hypothesis that aggregated Aβ is one of the
players triggering degradation of synapses.5,6 AD presymptom-
atic phase may last a decade or even more, and it is during this
early phase, before the irreversible changes occur, therapies are
most likely to be effective. In this study, we tested if preventive
treatment with G4HisMal can protect APP/PS1 mice from
memory impairment. Previously, maltose modified PPI dendri-
mers (G3Mal and G4Mal) have been suggested as promising
modulators for the formation of the amyloid fibrillar structures
related to certain proteinopathies diseases such as AD and prion
diseases.12,35 The interaction of G3Mal and G4Mal dendrimers
with amyloid peptides is mainly tailored by hydrogen bonds
depending on the density of hydrogen bond-forming sugar
groups on the dendrimer surface.36 However, being able to cross
BBB and to interfere with Aβ, G3Mal does not improve clinical
symptoms in vivo.12 Therefore, we synthesized a novel type of
dendrimers: 4th generation of PPI dendrimers with maltose-
histidine shell, G4HisMal. In this study, we explored in vitro and
in vivo the effects of G4HisMal. Our first objective was to assess
whether histidine on the dendrimer shell can improve thebiocompatibility and the ability to cross BBB of the precursor
dendrimer G3Mal. The second objective was to investigate the
potential of G4HisMal to protect AD transgenic mice from
memory impairment. In vivo evaluations demonstrated that
histidine maltose shell significantly improved biocompatibility
and ability to cross BBB of PPI dendrimers; G4HisMal were able
to interfere with Aβ fibril formation in vitro and in vivo; finally,
chronic treatment with G4HisMal protected APP/PS1 mice from
memory impairment. Since synaptic markers such as Psd95,
synaptophysin, and drebrin were preserved after the G4HisMal
treatment in AD transgenic mice, we suggest that the mechanism
behind memory protection could be synapse shielding from
soluble Aβ neurotoxicity.
The loss of synaptophysin immunoreactivity is the best-
known correlate of cognitive decline in human AD2 and, in AD
transgenic models, synaptic markers such as synaptophysin and
Psd-95 are also shown to be reduced.34 Moreover, Psd95
knockout animals have learning defects and impaired basal
synaptic transmission37; transgenic animals lacking synaptophy-
sin have increased exploratory behavior and reduced novel
object recognition.38
Interestingly, it has been shown that loss of synaptophysin
immunoreactivity clearly preceded plaque formation, raising the
possibility that Aβ can induce structural and functional neuronal
deficits independent of plaque formation. Therefore, a treatment
which may protect synapses is one of the avenues to fight against
memory decline during AD.3,39
Here, three months of treatment with G4HisMal was able to
prevent a decrease in synaptophysin and Psd95 synaptic markers
compared to PBS-treated APP/PS1 mice. G4HisMal did not
Figure 6. G4HisMal treatment protects synapses in APP/PS1 mice. Representative dot and Western blots of Psd95, drebrin, and synaptophysin. β-actin was used
for protein normalization Statistics: Student’s t-test. (n = 4-6 animals per group, dot and western blotting was done in triplicate). Data are expressed as a mean ±
SD. Dot Blots and Western blots of Psd95, drebrin, synaptophysin for wild-type animals are shown in the Supplementary Figure 12.
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mice indicating that most likely the levels of mRNA expression
of synaptic markers were not changed. Therefore, the increased
levels of Psd95, Synaptophysin, Drebrin in treated APP/PS1
mice compared to the control group are more likely an effect of
reduced degradation of synapses. Importantly, our results were
reproducible, in two independent experiments we got similar
results demonstrating memory protection after G4HisMal
treatment.
However, since the analysis of mRNA expression of synaptic
markers was not possible in this study due to brain homogenate
preparation, future experiments are required to determine
thoroughly what mechanism(s) is/are behind the protection of
synapses by G4HisMal. Also, the interaction of G4HisMal with
soluble Aβ pool should be further assessed in vivo including the
response of neurons, astrocytes, and microglia.
To conclude, we demonstrated that histidine-maltose shell
significantly improves biocompatibility of PPI dendrimers and
their ability to cross BBB. Therefore, we suggest that maltose-
histidine shell may be used to improve biocompatibility and
ability to cross BBB of other types of dendrimers. We provedthat during chronic administration (during three months) of
G4HisMal was able to cross BBB and G4HisMal treatment
rescued spatial memory deficits in APP/PS1 mice possibly via
shielding of synapses against soluble Aβ oligomers. Thus,
G4HisMal is an effective and safe agent suitable for treatment of
the central nervous system.Acknowledgments
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